Reprogram Biosciences Closes Seed Financing to Advance Tumor Cell Reprogramming Therapeutics June 2, 2026
Adcendo ApS Announces Collaboration with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA in Ph 1b Study in Patients with Advanced Solid Tumors June 2, 2026
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours May 26, 2026
First patients dosed with [212Pb]VMT-α-NET and [212Pb]PSV359 in two new cohorts of Ph 1/2a studies in neuroendocrine tumors and solid tumors May 26, 2026
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline May 26, 2026
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload May 26, 2026
HREC Australia approves HLX3902 for Clinical Trial in Australia in metastatic CRPC and other advanced solid tumours May 26, 2026
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas May 21, 2026
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA May 12, 2026
Cytospire Therapeutics oversubscribed £61M ($83m) Series A financing to advance pan-gamma delta T cell engagers into clinical trials for the treatment of cancer May 12, 2026
Signadori Bio Raises €11 Million Seed Round to Advance Next-Generation Solid Tumour Platform May 12, 2026
Kanvas Biosciences Secures $48M Series A to Deliver Novel Microbiome Therapeutics to Cancer Patients May 12, 2026
TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors April 28, 2026
ADCE-T02 enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors April 28, 2026
